The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer
Authors:
- 1 August 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (15) , 4998-5003
Abstract
Purpose: The circulating soluble form of intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) are elevated in women with breast cancer and associated with tumor progression and poor prognosis. This study examined the effects of anthracycline-based chemotherapy on plasma sICAM-1 and VEGF, as well as soluble P-selectin, von Willebrand factor, and interleukin-6 levels. Experimental Design: Twenty-six women diagnosed with stage I–IIIA breast cancer (mean age, 48.4 ± 10.4 years; range, 34–79 years) were studied before (week 1) and at weeks 2 and 3 of cycles 1 and 4 of chemotherapy. Results: The initial effect of chemotherapy was to reduce sICAM-1 levels; compared with pretreatment, sICAM-1 levels were decreased at week 2 of both cycles (P values < 0.01). sICAM-1 levels were elevated, however, at the start of cycle 4 as compared with pretreatment (P < 0.01). Chemotherapy led to an increase in sICAM-1 levels in node-positive but not node-negative patients (P < 0.01). VEGF levels were decreased at week 2 of cycle 4 (P = 0.001) and remained so at week 3. Similar to sICAM-1, VEGF levels were elevated at the start of cycle 4 as compared with pretreatment (P < 0.006). Soluble P-selectin levels decreased during week 2 of cycle 4 (P = 0.026). Neither interleukin-6 or von Willebrand factor were significantly changed in response to chemotherapy. Conclusions: The findings support prior studies suggesting that sICAM-1 levels derive from sources other than endothelial cells. In addition, whereas the more immediate effect of chemotherapy is to reduce sICAM-1 and VEGF, continued treatment may lead to significant elevations.Keywords
This publication has 37 references indexed in Scilit:
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Effects of cytarabine and various anthracyclins on platelet activation: Characterization ofin vitro effects and their possible clinical relevance in acute myelogenous leukemiaInternational Journal of Cancer, 2001
- Structure of von Willebrand factor and its function in platelet adhesion and thrombus formationBest Practice & Research Clinical Haematology, 2001
- Prognostic Value of Vascular Endothelial Growth Factor in Breast CancerThe Oncologist, 2000
- The increased expression of adhesion molecules ICAM‐3, E‐ and P‐selectins on breast cancer endotheliumThe Journal of Pathology, 1995
- Serum concentrations of E‐selectin, P‐selectin, ICAM‐1 and interleukin 6 in acute leukaemia patients with chemotherapy‐induced leucopenia and bacterial infectionsBritish Journal of Haematology, 1995
- The Significance of Soluble lnterleukin-2, Soluble Interleuk in-2 Receptors, Soluble ICAM-1 and β2-Microglobulin in Breast Cancer PatientsTumor Biology, 1995
- Regulation of ICAM‐1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast‐derived factorsInternational Journal of Cancer, 1994
- Prevention of Activated Neutrophil Adhesion to Endothelium by Soluble Adhesion Protein GMP140Science, 1990